Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update
{{output}}
Introduction: In a previous publication, we provided an overview of the current situation of patient access to orphan drugs in the European Union (EU), of the evolving rare disease policy landscape and recommendations for areas o... ...
